AstraZeneca Exceeds Expectations with Strong Drug Sales and US Demand
AstraZeneca (AZN.L) exceeded expectations for second-quarter revenue and profit on Tuesday, notably driven by strong sales of its cancer, heart, and kidney disease drugs and high demand in the US. The company
